Activation status of eosinophils in severe asthma patients treated with biologics
- Conditions
- Severe asthma Mild asthma
- Registration Number
- JPRN-UMIN000040859
- Lead Sponsor
- Department of respiratory medicine, University of Tsukuba Hospital
- Brief Summary
We evaluated the variation in gene expression profiles of peripheral blood eosinophils before and after starting treatment with mepolizumab. The expression of genes associated with IL-5/IL-5R signaling was decreased in eosinophils of patients treated with mepolizumab compared to that before starting mepolizumab. In contrast, genes particularly associated with type 1 eosinophils were upregulated after treatment with mepolizumab.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 27
Not provided
Exclusion criteria for all participant group 1. Concurrent Respiratory Disease: Presence of a known pre-existing, clinically important lung condition other than asthma. 2. Malignancy: A current malignancy or previous history of cancer in remission for less than 12 months prior to screening. 3. Liver Disease: Known, pre-existing, unstable liver disease. 4. Cardiovascular: Subjects who have severe or clinically significant cardiovascular disease uncontrolled with standard treatment. 5. Other Concurrent Medical Conditions: Subjects who have known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological or any other system abnormalities that are uncontrolled with standard treatment. 6. Eosinophilic Diseases: Subjects with other conditions that could lead to elevated eosinophils such as hyper-eosinophilic syndrome, Churg-Strauss syndrome, or eosinophilic esophagitis. 7. Pregnancy: Subjects who are pregnant or breastfeeding. Specific exclusion criteria for each group Participant group 3 (N = 3 for each biologic, total N=9), 1. Participants who have received any biologics (mepolizumab, omalizumab, benralizumab, or dupilumab) within 56 days before Visit 1.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Elucidation of the phenotypic heterogeneity of circulating eosinophils in severe asthma and mild asthma by performing RNA-seq in whole blood cells and purified blood eosinophils.
- Secondary Outcome Measures
Name Time Method Subsequent evaluation of the phenotypic alterations of blood eosinophils after treatment with the biologics mepolizumab, omalizumab, and dupilumab.